Skip to main content
. Author manuscript; available in PMC: 2010 Jul 19.
Published in final edited form as: Clin Liver Dis. 2009 Aug;13(3):467–475. doi: 10.1016/j.cld.2009.05.010

Fig. 3.

Fig. 3

Four patients with NASH were treated with IDN-6556 at a dose of 100 mg orally twice a day. Changes in the serum ALT values are expressed as a percent change from baseline. Results are the mean ± SEM in 4 patients. (Reprinted from Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007;46(2):327; with permission.)